Predicting adverse events of cancer medicines: a secondary analysis of clinical trial data

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-E-033-Monday
• By: SORICH, Michael (Flinders University, Adelaide, Australia)
• Co-author(s): Michael Sorich: Clinical Pharmacology, Flinders University, Adelaide, Australia
  Andrew Rowland: Clinical Pharmacology, Flinders University, Adelaide, Australia
  Ganessan Kichenadasse: Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia
  Richard Woodman: Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia
  Arduino Mangoni: Clinical Pharmacology, Flinders University, Adelaide, Australia
  
• Abstract:

  Backgrounds

  Secondary analysis of pooled clinical trial data is an important means of identifying patient characteristics and laboratory/biological markers that predict individuals at greatest risk of toxicities from cancer medicines. 

  Aims

  To evaluate risk factors for proteinuria in patients with metastatic renal cell carcinoma (mRCC) treated with a
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login